AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Esophageal Hypersensitivity Study in Healthy Volunteers

Phase 1

Completed

Conditions: Pain
Esophageal Sensitivity

Interventions: Drug: AZD1386
Drug: Placebo

First Posted Date: 2008-07-08

Last Posted Date: 2009-08-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 45

Registration Number: NCT00711048

Locations: 🇸🇪
Research Site, Goteborg, Sweden

Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: AZD5672

First Posted Date: 2008-07-08

Last Posted Date: 2009-04-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 4

Registration Number: NCT00711074

Locations: 🇬🇧
Research Site, Macclesfield, Cheshire, United Kingdom

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Melanoma
Malignant Melanoma

Interventions: Drug: AZD6244

First Posted Date: 2008-07-04

Last Posted Date: 2014-08-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT00710515

Locations: 🇬🇧
Research Site, Oxford, United Kingdom

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasm Metastasis

Interventions: Drug: AZD2281
Drug: Bevacizumab

First Posted Date: 2008-07-04

Last Posted Date: 2015-01-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT00710268

Locations: 🇬🇧
Research Site, Oxford, United Kingdom

Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: midazolam
Drug: ZD4054

First Posted Date: 2008-07-03

Last Posted Date: 2010-09-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 12

Registration Number: NCT00709553

Locations: 🇩🇪
Research Site, Berlin, Germany

Food Effect Study of a Single Dose of ZD4054 (Zibotentan)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ZD4054

First Posted Date: 2008-07-03

Last Posted Date: 2010-11-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT00710047

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

An Interaction Study of Ketoconazole/Verapamil Versus AZD1305

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ketoconazole
Drug: Verapamil
Drug: AZD1305

First Posted Date: 2008-07-01

Last Posted Date: 2010-12-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT00707551

Locations: 🇩🇪
Research Site, Berlin, Germany

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: AZD2281
Drug: Paclitaxel

First Posted Date: 2008-07-01

Last Posted Date: 2018-03-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 19

Registration Number: NCT00707707

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Terminated

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Once-daily aclidinium/formoterol
Drug: Twice-daily formoterol fumarate
Drug: Placebo to formoterol fumarate
Drug: Once-daily formoterol fumarate

First Posted Date: 2008-06-30

Last Posted Date: 2017-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 156

Registration Number: NCT00706914

Locations: 🇺🇸
Forest Investigative Site, Milwaukee, Wisconsin, United States

AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: AZD0530

First Posted Date: 2008-06-24

Last Posted Date: 2011-05-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT00704366

Locations: 🇯🇵
Research Site, Sunto-gun, Shizuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy